Literature DB >> 16174482

Inflammatory neuropathies: an update on evaluation and treatment.

Lisa D Hobson-Webb1, Peter D Donofrio.   

Abstract

Inflammatory neuropathies are a diverse group of illnesses sharing the pathologic characteristic of inflammation surrounding nerve fibers. They may be autoimmune, granulomatous, infectious, paraneoplastic, or paraproteinemic in origin. All can result in significant morbidity and rarely, death. It is critical to correctly diagnose these illnesses, as many respond well to treatment. In this paper, the diagnosis and latest developments in the treatment of the most common inflammatory neuropathies (Guillain-Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, neurosarcoidosis, anti-myelin-associated glycoprotein neuropathy, Sjögren's syndrome, paraneoplastic neuronopathy, and vasculitic neuropathies) will be discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16174482     DOI: 10.1007/s11926-005-0019-6

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  64 in total

1.  Rituximab-responsive CIDP.

Authors:  C Briani; G Zara; R Zambello; L Trentin; M Rana; F Zaja
Journal:  Eur J Neurol       Date:  2004-11       Impact factor: 6.089

2.  High-dose i.v. immunoglobulin for peripheral neuropathy associated with Sjögren's syndrome.

Authors:  J Pascual; C Cid; J Berciano
Journal:  Neurology       Date:  1998-08       Impact factor: 9.910

3.  Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis.

Authors:  N Mowzoon; A Sussman; W G Bradley
Journal:  J Neurol Sci       Date:  2001-04-01       Impact factor: 3.181

4.  Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies.

Authors:  Susanne Renaud; Michael Gregor; Peter Fuhr; Delia Lorenz; Günther Deuschl; Alois Gratwohl; Andreas J Steck
Journal:  Muscle Nerve       Date:  2003-05       Impact factor: 3.217

5.  Treatment experience in patients with anti-myelin-associated glycoprotein neuropathy.

Authors:  K C Gorson; A H Ropper; D H Weinberg; R Weinstein
Journal:  Muscle Nerve       Date:  2001-06       Impact factor: 3.217

6.  Peripheral neuropathy in systemic lupus erythematosus--a longitudinal study.

Authors:  R Omdal; S Løseth; T Torbergsen; W Koldingsnes; G Husby; S I Mellgren
Journal:  Acta Neurol Scand       Date:  2001-06       Impact factor: 3.209

7.  Anti-Hu antibody neuropathy: a clinical, electrophysiological, and pathological study.

Authors:  Shin J Oh; Yasar Gürtekin; Edward J Dropcho; Peter King; Gwendolyn C Claussen
Journal:  Clin Neurophysiol       Date:  2005-01       Impact factor: 3.708

Review 8.  Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy.

Authors:  Kenneth C Gorson; Anthony A Amato; Allan H Ropper
Journal:  Neurology       Date:  2004-08-24       Impact factor: 9.910

9.  Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients.

Authors:  Loïc Guillevin; Pascal Cohen; Alfred Mahr; Jean-Pierre Arène; Luc Mouthon; Xavier Puéchal; Edouard Pertuiset; Brigitte Gilson; Mohamed Hamidou; Patricia Lanoux; Alain Bruet; Marc Ruivard; Philippe Vanhille; Jean-François Cordier
Journal:  Arthritis Rheum       Date:  2003-02-15

10.  Positive salivary gland biopsy, Sjögren syndrome, and neuropathy: clinical implications.

Authors:  Kenneth C Gorson; Allan H Ropper
Journal:  Muscle Nerve       Date:  2003-11       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.